Daewoong Pharmaceutical's New IPF Drug Versiporosin Completes Global Phase 2 Enrollment with 104 Patients

First Public Disclosure of IPF Patient Characteristics in Korea and the United States
Top-line Results to Be Announced in the First Half of 2027
Includes Both Patients Using and Not Using Existing Anti-fibrotic Agents

Daewoong Pharmaceutical has completed patient enrollment for the global Phase 2 clinical trial of Versiporosin (DWN12088), its investigational treatment for idiopathic pulmonary fibrosis (IPF), and has released the characteristics of all enrolled patients.

Professor Moosuk Park of the Department of Pulmonology at Severance Hospital is presenting the analysis results of the overall enrolled patient characteristics from the Phase 2 global clinical trial of Vericfosolsin at ERS 2026. Severance Hospital

On September 6 (local time), Daewoong Pharmaceutical announced that it had presented, in poster format, the results of an analysis on the clinical and functional characteristics of 104 IPF patients enrolled in Korea and the United States at the European Respiratory Society (ERS 2026) meeting held in Barcelona, Spain.

The total patient population consisted of 55 patients from Korea (52.9%) and 49 from the United States (47.1%). Seventy-one patients (68.3%) were receiving existing anti-fibrotic agents, while 33 patients (31.7%) were not. The average forced vital capacity (FVC) was approximately 77% of the normal predicted value, and the diffusing capacity for carbon monoxide (DLCO) was about 51%. Baseline characteristics were generally similar between the anti-fibrotic agent user and non-user groups.

Versiporosin is an investigational compound that selectively inhibits prolyl-tRNA synthetase (PRS), thereby reducing collagen production. The Phase 2 trial is being conducted in Korea and the United States using a randomized, double-blind, placebo-controlled design. Patients are administered Versiporosin or placebo twice daily for 24 weeks, and concomitant use of existing anti-fibrotic agents such as pirfenidone or nintedanib is permitted.

This analysis presents the baseline characteristics of all enrolled patients prior to disclosure of the Phase 2 trial's efficacy and safety results. Daewoong Pharmaceutical is currently expediting completion of the trial and plans to announce the top-line results in the first half of 2027.

Versiporosin has been designated an orphan drug and granted fast track status by the U.S. Food and Drug Administration (FDA), and has also received orphan drug designation from the European Medicines Agency (EMA).

This content was produced with the assistance of AI translation services.